drugset / Trial / NCT06987916

Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma

NCT06987916

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label phase1 study to assess the safety and efficacy of U01(ssCART-19) cell therapy in the treatment of patients with refractory or recurrent B-cell lymphoma .

Timeline

Start
2025-04-22
Primary completion
2028-04-22
Completion
2030-04-22

Drugs

EvaluationDrugModalityDoseRoute
Subject ssCART-19 Cell therapy

Indications